| For: | Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol 2016; 22(36): 8211-8218 [PMID: 27688663 DOI: 10.3748/wjg.v22.i36.8211] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i36/8211.htm |
| Number | Citing Articles |
| 1 |
Chenthan Krishnakumar, Ashwin N. Ananthakrishnan, Brendan M. Boyle, Anne M. Griffiths, Neal S. LeLeiko, David R. Mack, James F. Markowitz, Joel R. Rosh, Cary G. Sauer, Thomas D. Walters, Erin Bonkowski, Lee A. Denson, Jeffrey S. Hyams, Subra Kugathasan. Early Change in Fecal Calprotectin Predicts One‐Year Outcome in Children Newly Diagnosed With Ulcerative Colitis. Journal of Pediatric Gastroenterology and Nutrition 2022; 74(1) doi: 10.1097/MPG.0000000000003291
|
| 2 |
Gregory Rosenfeld, Neeraj Narula, Yvette Leung, Waqqas Afif, Astrid-Jane Williams, Vivian Huang, Harminder Singh, Jeffrey D. McCurdy, Vipul Jairath, Mindy Lam, Dustin E. Loomes, Petros Zezos, Michael Stewart, Christopher Ma, Mark Ropeleski, Maria Ancheta-Schmit, Pedram Tavakoli, Jeffrey N. Bone, James D. Lewis, Jean-Frederic Colombel, Brian Bressler. Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial. Gastroenterology 2026; doi: 10.1053/j.gastro.2026.06.006
|
| 3 |
Barry D Kyle, Terence A Agbor, Shajib Sharif, Usha Chauhan, John Marshall, Smita L S Halder, Stephen Ip, Waliul I Khan. Fecal Calprotectin, CRP and Leucocytes in IBD Patients: Comparison of Biomarkers With Biopsy Results. Journal of the Canadian Association of Gastroenterology 2021; 4(2) doi: 10.1093/jcag/gwaa009
|
| 4 |
Satwik Motaganahalli, Lauren Beswick, Danny Con, Daniel R. van Langenberg. Faecal calprotectin delivers on convenience, cost reduction and clinical decision‐making in inflammatory bowel disease: a real‐world cohort study. Internal Medicine Journal 2019; 49(1) doi: 10.1111/imj.14027
|
| 5 |
Wei Zhang, Chiew Hsia Wong, Mallory Chavannes, Tima Mohammadi, Greg Rosenfeld. Cost-effectiveness of faecal calprotectin used in primary care in the diagnosis of inflammatory bowel disease. BMJ Open 2019; 9(4) doi: 10.1136/bmjopen-2018-027043
|
| 6 |
Anna Luisa Bathe, Eirini Mavropoulou, Nicolae-Catalin Mechie, Golo Petzold, Volker Ellenrieder, Steffen Kunsch, Ahmad Amanzada, Bruno Bonaz. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn’s disease and ulcerative colitis. PLOS ONE 2019; 14(10) doi: 10.1371/journal.pone.0223893
|
| 7 |
Waqqas Afif, Bernie Sattin, Dorota Dajnowiec, Reena Khanna, Cynthia H. Seow, Martin Williamson, Kinda Karra, Yanli Wang, Long-long Gao, Brian Bressler. Ustekinumab Therapeutic Drug Monitoring—Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. Digestive Diseases and Sciences 2022; 67(7) doi: 10.1007/s10620-021-07173-1
|
| 8 |
Karoline Freeman, Brian H Willis, Hannah Fraser, Sian Taylor-Phillips, Aileen Clarke. Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy. BMJ Open 2019; 9(3) doi: 10.1136/bmjopen-2018-027428
|
| 9 |
Katarzyna Lewandowska, Olga Ciepiela. The correlation between the concentration of faecal calprotectin and markers of inflammation in children with gastrointestinal disorders. Diagnostyka Laboratoryjna 2017; 53(2) doi: 10.5604/01.3001.0013.7968
|
| 10 |
S. P. Jerkic, F. Michel, H. Donath, E. Herrmann, R. Schubert, M. Rosewich, S. Zielen. Calprotectin as a New Sensitive Marker of Neutrophilic Inflammation in Patients with Bronchiolitis Obliterans. Mediators of Inflammation 2020; 2020 doi: 10.1155/2020/4641585
|
| 11 |
Agnieszka Wierzbicka, Artur Uździcki. A new uses of calprotectin as an inflammation biomarker. Diagnostyka Laboratoryjna 2023; 58(4) doi: 10.5604/01.3001.0053.5970
|